### **BEST AVAILABLE COPY**

PCT/US00/22583

#### **PATENT COOPERATION TREATY**

	From the INTERNATIONAL BUREAU
PCT	То:
NOTIFICATION OF ELECTION (PCT Rule 61.2)	Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202
Date of mailing (day/month/year)	ETATS-UNIS D'AMERIQUE in its capacity as elected Office
11 July 2001 (11.07.01)	
International application No. PCT/US00/22583	Applicant's or agent's file reference GMV-003.25
International filing date (day/month/year)	Priority date (day/month/year)
17 August 2000 (17.08.00)	25 August 1999 (25.08.99)
Applicant	
NICOLAU, Yves, Claude et al	
X in the demand filed with the International Prelimina 23 March 20  in a notice effecting later election filed with the Inte	01 (23.03.01)
2. The election X was was not was not made before the expiration of 19 months from the priority Rule 32.2(b).	r date or, where Rule 32 applies, within the time limit under
	·
The International Bureau of WIPO	Authorized officer
34, chemin des Colombettes	H. Zhou
Facsimile No : (41,22) 740 14 35	Telephone No. (41 22) 220 22 23

Form PCT/IB/331 (July 1992)

US0022583



## **PCT**

REC'D 19 OCT 2001

### INTERNATIONAL PRELIMINARY EXAMINATION PREPORT

(PCT Article 36 and Rule 70)

14

Applicant's or agent's file reference	Saa	Notification of Transmittal of International
GMV-003.25		iminary Examination Report (Form PCT/IPEA/416)
International application No.	International filing date (day/month/year)	Priority date (day/month/year)
PCT/US00/22583	17/08/2000	25/08/1999
International Patent Classification (IPC) or no A61K31/575	ational classification and IPC	·
GMP COMPANIES, INC. et al.		
This international preliminary examinand is transmitted to the applicant a	ination report has been prepared by thi according to Article 36.	s International Preliminary Examining Authority
2. This REPORT consists of a total of	5 sheets, including this cover sheet.	
been amended and are the bas	d by ANNEXES, i.e. sheets of the descr is for this report and/or sheets containing or of the Administrative Instructions und	ription, claims and/or drawings which have ng rectifications made before this Authority der the PCT).
These annexes consist of a total of	sheets.	
3. This report contains indications relat	ing to the following items:	
I ☒ Basis of the report		
II Priority		• .
III   Non-establishment of op	pinion with regard to novelty, inventive s	step and industrial applicability
IV Lack of unity of invention	ו	·
V ⊠ Reasoned statement und citations and explanation	der Article 35(2) with regard to novelty, as suporting such statement	inventive step or industrial applicability;
VI D Certain documents cited		·
VII   Certain defects in the int	ernational application	
VIII   Certain observations on	the international application	
Date of submission of the demand	Date of completio	n of this report
23/03/2001	17.10.2001	
lame and mailing address of the International reliminary examining authority:	Authorized officer	The same of the sa
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 e Fax: +49 89 2399 - 4465	1	
	Telephone No. +4	9 89 2399 8275

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

',j

International application No. PCT/US00/22583

I.	В	asis of the report	
1	th ai	ie receiving Office in	ments of the international application (Replacement sheets which have been furnished to response to an invitation under Article 14 are referred to in this report as "originally filed" to this report since they do not contain amendments (Rules 70.16 and 70.17)):
	1-	48	as originally filed
	CI	laims, No.:	· ·
	1-	49	as originally filed
	Dr	rawings, sheets:	
	1-2	2	as originally filed
		:	
2.	Wi	th regard to the lang guage in which the i	uage, all the elements marked above were available or furnished to this Authority in the nternational application was filed, unless otherwise indicated under this item.
	Th	ese elements were a	vailable or furnished to this Authority in the following language: , which is:
		the language of a t	ranslation furnished for the purposes of the international search (under Rule 23.1(b)).
		the language of pu	blication of the international application (under Rule 48.3(b)).
		the language of a t 55.2 and/or 55.3).	ranslation fumished for the purposes of international preliminary examination (under Rule
3.	Wit	th regard to any nuc ernational preliminan	leotide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing:
		contained in the int	ernational application in written form.
		filed together with t	he international application in computer readable form.
		furnished subseque	ently to this Authority in written form.
		furnished subseque	ently to this Authority in computer readable form.
	□.	The statement that the international ap	the subsequently furnished written sequence listing does not go beyond the disclosur in plication as filed has been furnished.
		The statement that listing has been fun	the information recorded in computer readable form is identical to the written sequence nished.
	The	amendments have	resulted in the cancellation of:
		the descripti n,	pages:
1		the claims.	Nos.:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/22583

		the drawings,	sheets:						
5.		This report has been considered to go bey	establish ond the c	ed as if (s disclosure	some of) t as filed (l	he amendmer Rule 70.2(c)):	nts had not bee	n made, since they have	bee
		(Any replacement she report.)	eet conta	ining sucl	n amendn	ents must be	referred to und	ler item 1 and annexed to	this
6.	Add	itional observations, if	necessa	ry:					
V.	Rea citat	soned statement und tions and explanation	der Articl	le 35(2) w orting suc	ith regar ch statem	d to novelty,	Inventive step	or industrial applicabili	ty;
1.	State	ement							
	Nove	elty (N)	Yes: No:	Claims Claims	1-49		· ·		
	Inve	ntive step (IS)	Yes: No:	Claims Claims	1-49				
	Indu	strial applicability (IA)	Yes: No:	Claims Claims	1-49				

2. Citations and explanations see separate sheet

#### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet

# INTERNATIONAL PRELIMINARY International application No. PCT/US00/22583 EXAMINATION REPORT - SEPARATE SHEET

possess this property (Article 33 (3) PCT).

#### PATENT COOPERATION TREATY

## PCT

#### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification of (Form PCT/ISA/2	of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 00/22583	17/08/2000	25/08/1999
Applicant	•	*
GMP COMPANIES, INC. et al.		
This International Search Report has beer according to Article 18. A copy is being tra	prepared by this International Searching Authorsmitted to the International Bureau.	nority and is transmitted to the applicant
	of a total of <u>8</u> sheets. a copy of each prior art document cited in this	report.
Basis of the report		
language in which it was filed, unle	nternational search was carried out on the bas iss otherwise indicated under this Item.	is of the international application in the
the international search was Authority (Rule 23.1(b)).	as carried out on the basis of a translation of th	ne international application furnished to this
was carned out on the basis of the	I/or amino acid sequence disclosed in the int sequence listing: nal application in written form.	ternational application, the international search
==	national application in computer readable form	1.
furnished subsequently to	this Authority in written form.	
_	this Authority in computer readble form.	
the statement that the sub-	sequently furnished written sequence listing do filed has been furnished.	oes not go beyond the disclosure in the
_		identical to the written sequence listing has been
2. X Certain claims were foun	d unsearchable (See Box I).	
3. Unity of invention is lack		
4. With regard to the title,		
the text is approved as sub	mitted by the applicant.	
	ed by this Authority to read as follows:	
AGENTS FOR THE ENHANCED	O OXYGEN DELIVERY IN MAMMALS	5
5. With regard to the abstract.		
X the text is approved as sub	nitted by the applicant.	1
the text has been established	ed, according to Rule 38.2(b), by this Authority late of mailing of this international search repo	as it appears in Box III. The applicant may, rt, submit comments to this Authority.
6. The figure of the drawings to be published.	ned with the abstract is Figure No.	·
as suggested by the applica		X None of the figures.
because the applicant failed	•	,
because this figure better c	laracterizes the invention.	

Form PCT/ISA/210 (first sheet) (July 1998)

International application No. PCT/US 00/22583

#### INTERNATIONAL SEARCH REPORT

Box I Obs rvati ns wh re certain claim w r found unsearchable (C ntinuati n of item 1 f first sheet)
. This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.:  - Claims Nos.:  because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple Inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable dalms could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
· · · · · · · · · · · · · · · · · · ·
·
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

international Application No PCT/US 00/22583

a. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/575 A61K31/70 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 0 338 916 A (INSTITUT MERIEUX) 1 - 4925 October 1989 (1989-10-25) claims 1-34 Y WO 97 42819 A (A. HACES) 1 - 4920 November 1997 (1997-11-20) claims 1-19 Y WO 98 39358 A (GENTA INC.) 1 - 4911 September 1998 (1998-09-11) claims 1-38 Y WO 98 39359 A (GENTA INC.) 1-49 11 September 1998 (1998-09-11) claims 1-41 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the 'A' document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international \*X° document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to filing date document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-'O' document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed in the art. \*&\* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 18 2. nz. nr 2 January 2001 Name and mailing address of the ISA Authorized officer European Palent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Herz, C

International Application No PCT/US 00/22583

Category *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
Υν	EP 0 452 055 A (HEWLETT-PACKARD CO.) 16 October 1991 (1991-10-16) claims 1-16	1-49
Y ,	US 5 612 207 A (Y. C. NICOLAU ET AL.) 1/8 March 1997 (1997-03-18) column 23, line 15 -column 24, line 25	1-49
· ~	US 5 927 283 A (D. J. ABRAHAM, M. GERBER) 27 July 1999 (1999-07-27) claims 1,2; tables 1-7	1-49
1 /	US 5 872 282 A (D. J. ABRAHAM ET AL.) 16 February 1999 (1999-02-16) tables 1-7	1-49
( J	US 5 110 909 A (E. DELLACHERIE ET AL.) 5 May 1992 (1992-05-05) claims 1-23	1-49
' レ	US 4 921 997 A (I. LALEZARI, P. LALEZARI) 1 May 1990 (1990-05-01) table 1	1-49
1 /	US 5 079 337 A (M. LEONARD ET AL.) 7 January 1992 (1992-01-07) claims 1-29	1-49
	PATENT ABSTRACTS OF JAPAN vol. 017, no. 119, 12 March 1993 (1993-03-12) & JP 04 300838 A (TERUMO CORP.), 23 October 1992 (1992-10-23) abstract	1-49
	E. ANTONINI ET AL.: "The Effect of Anions and Cations on the Oxygen Equilibrium of Human Hemoglobin" OXYGEN AFFINITY HEMOGLOBIN RED CELL ACID BASE STATUS, PROC. ALFRED BENZON SYMP., 4TH (25YHA4), 1972, pages 121-130, XP000944291 figures 1-4	1-49
! Y	N. OUDHIRI ET AL.:  "Guanidinium-cholesterol cationic lipids: novl reagents for gene transfection and perspectives for gene therapy" BIOGENIC AMINES,	1-49
	- vol. 14, no. 5, 1998, pages 537–552, XP000944064 figure 1 ———	
	-/	

International Application No PCT/US 00/22583

Cicontinuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category** Citation of document, with indication, where appropriate, of the relevant passages  Relevant to claim No.  Y W. J. FANTL ET AL.: "Specifically Carboxymethylated Hemoglobin as an Analogue of Carbamino Hemoglobin" J. BIOL. CHEM., vol. 262, no. 26, 1987, pages 12700–12713, X*P000943847  page 12700  Y K. UCHIDA ET AL.: "Effect of an Allosteric Modifier of Hemoglobin, RSR-4, on Oxygen Affinity and Oxygen Saturation of Hemoglobin in Rabbits" JPN. J. PHYSIOL., vol. 48, no. 6, 1998, pages 439–444, X*P000943772  table 2  Y I. PAPASSOTIRIOU ET AL.: "Synthesized allosteric effectors of the hemoglobin molecule: A possible mechanism for improved erythrocyte oxygen release capability in hemoglobinopathy H disease" EXPERIMENTAL HEMATOLOGY, vol. 26, no. 10, 1998, pages 922–926, X*P000943784  figures 1-4; tables 1,2  Y I. TABUSHI ET AL.: "Artificial Allosteric Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type" MOL. STRUCT. ENERG., vol. 10, 1988, pages 195–218, X*P000943789  tables 7-6  C. NADOLNY ET AL.: "Specific Interactions of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study"			PC1/US 00/22583
Y W. J. FANTL ET AL.: "Specifically Carboxymethylated Hemoglobin as an Analogue of Carbamino Hemoglobin"  J. BIOL. CHEM., vol. 262, no. 26, 1987, pages 12700-12713, XP000943847   page 12700  Y K. UCHIDA ET AL.: "Effect of an Allosteric Modifier of Hemoglobin, RSR-4, on Oxygen Affinity and Oxygen Saturation of Hemoglobin in Rabbits"  JPN. J. PHYSIOL., vol. 48, no. 6, 1998, pages 439-444, XP000943772   table 2  Y I. PAPASSOTIRIOU ET AL.: "Synthesized allosteric effectors of the hemoglobin molecule: A possible mechanism for improved erythrocyte oxygen release capability in hemoglobinopathy H disease"   EXPERIMENTAL HEMATOLOGY, vol. 26, no. 10, 1998, pages 922-926, XP000943784   figures 1-4; tables 1,2  Y I. TABUSHI ET AL.: "Artificial Allosteric Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type"   MOL. STRUCT. ENERG., vol. 10, 1988, pages 195-218, XP000943789   tables 7-6  C. NADOLNY ET AL.: "Specific Interactions of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study"	ontinuation)	n) DOCUMENTS CONSIDERED TO BE RELEVANT	
Carboxymethylated Hemoglobin as an Analogue of Carbamino Hemoglobin"  J. BIOL. CHEM., vol. 262, no. 26, 1987, pages 12700-12713, Xf000943847 page 12700  Y. K. UCHIDA ET AL.: "Effect of an Allosteric Modifier of Hemoglobin, RSR-4, on Oxygen Affinity and Oxygen Saturation of Hemoglobin in Rabbits" JPN. J. PHYSIOL., vol. 48, no. 6, 1998, pages 439-444, Xf000943772 table 2  I. PAPASSOTIRIOU ET AL.: "Synthesized allosteric effectors of the hemoglobin molecule: A possible mechanism for improved erythrocyte oxygen release capability in hemoglobinopathy H disease" EXPERIMENTAL HEMATOLOGY, vol. 26, no. 10, 1998, pages 922-926, Xf000943784 figures 1-4; tables 1,2  I. TABUSHI ET AL.: "Artificial Allosteric Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type" MOL. STRUCT. ENERG., vol. 10, 1988, pages 195-218, Xf000943789 tables 7-6  C. NADOLNY ET AL.: "Specific Interactions of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study"	gory * Cita	tation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Allosteric Modifier of Hemoglobin, RSR-4, on Oxygen Affinity and Oxygen Saturation of Hemoglobin in Rabbits" JPN. J. PHYSIOL., vol. 48, no. 6, 1998, pages 439-444, XP000943772 table 2  I. PAPASSOTIRIOU ET AL.: "Synthesized allosteric effectors of the hemoglobin molecule: A possible mechanism for improved erythrocyte oxygen release capability in hemoglobinopathy H disease" EXPERIMENTAL HEMATOLOGY, vol. 26, no. 10, 1998, pages 922-926, XP000943784  figures 1-4; tables 1,2  I. TABUSHI ET AL.: "Artificial Allosteric Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type" MOL. STRUCT. ENERG., vol. 10, 1988, pages 195-218, XP000943789 tables 7-6  C. NADOLNY ET AL.: "Specific Interactions of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study"		Carboxymethylated Hemoglobin as an Analogue of Carbamino Hemoglobin"  J. BIOL. CHEM., vol. 262, no. 26, 1987, pages 12700-12713, XP000943847	1-49
allosteric effectors of the hemoglobin molecule: A possible mechanism for improved erythrocyte oxygen release capability in hemoglobinopathy H disease" EXPERIMENTAL HEMATOLOGY, vol. 26, no. 10, 1998, pages 922-926, XP000943784 figures 1-4; tables 1,2  I. TABUSHI ET AL.: "Artificial Allosteric Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type" MOL. STRUCT. ENERG., vol. 10, 1988, pages 195-218, XP000943789 tables 7-6  Y C. NADOLNY ET AL.: "Specific Interactions of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study"		Allosteric Modifier of Hemoglobin, RSR-4, on Oxygen Affinity and Oxygen Saturation of Hemoglobin in Rabbits" JPN. J. PHYSIOL., vol. 48, no. 6, 1998, pages 439-444, XP000943772	1-49
Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type" MOL. STRUCT. ENERG., vol. 10, 1988, pages 195-218, XP000943789 tables 7-6  C. NADOLNY ET AL.: "Specific Interactions of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study"	i c	allosteric effectors of the hemoglobin molecule: A possible mechanism for improved erythrocyte oxygen release capability in hemoglobinopathy H disease" EXPERIMENTAL HEMATOLOGY, vol. 26, no. 10, 1998, pages 922-926, XP000943784	1-49
of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study"	A 	Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type" MOL. STRUCT. ENERG., vol. 10, 1988, pages 195-218, XP000943789	1-24
BIOL. CHEM. HOPPE-SEYLER, vol. 374, no. 6, 1993, pages 403-407, xr000943782 * entire document *	2 H E	of the Allosteric Effector .  2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study" BIOL. CHEM. HOPPE-SEYLER, vol. 374, no. 6, 1993, pages 403-407, \$600943782	1-49
X. S. KILGORE ET AL.: "RSR13, a Synthetic Allosteric Modifier of Hemoglobin, Improves Myocardial Recovery Following Hypothermic Cardiopulmonary Bypass" CIRCULATION, SUPPL., vol. 100, no. 19, 1999, pages 351-356, XP000943791 figures 1-4; tables 1,2	A I H C	Allosteric Modifier of Hemoglobin, Improves Myocardial Recovery Following Hypothermic Cardiopulmonary Bypass" CIRCULATION, SUPPL., vol. 100, no. 19, 1999, pages 351-356, XP000943791 figures 1-4; tables 1,2	1-49
		·	

International Application No PCT/US 00/22583

		PC1/US 00/22583
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	D. L. CURRELL ET AL.: "Synthetic polyphosphonates, polyphosphates, and phosphonocarboxylates as allosteric effectors of hemoglobin" PHOSPHORUS, SULFUR SILICON RELAT. ELEM., vol. 51-52, no. 1-4, 1990, pages 35-38, XP000943807 tables I-IV	1-49
γ 🗸	A. N. CHUVILIN ET AL.: "Allosteric regulators of reversible hemoglobin oxygenation" BIOORG. KHIM., vol. 16, no. 9, 1990, pages 1157-1176, XP002156415 page 1176	1-49
Y	JP- VIGNERON ET AL.: "Guanidinium-cholesterol cationic lipids: Efficient vectors for the transfection of eukaryotic cells" PROC. NATL. ACAD. SCI. USA, vol. 93, no. 18, 1996, pages 9682-9686, XP002030510 * entire document *	1-49
Y	N. OUDRHIRI ET AL.: "Gene transfer by guanidinium-cholesterol cationic lipids into airway epithelial cells in vitro and in vivo" PROC. NATL. ACAD. SCI. USA, vol. 94, no. 5, 1997, pages 1651-1656, XP002035783  * entire document *	1-49
Y	B. PITARD ET AL.: "Structural characteristics of supramolecular assemblies formed by guanidinium-cholesterol reagents for gene transfection" PROC. NATL. ACAD. SCI. USA, vol. 96, no. 6, 1999, pages 2621-2626, XP000941540  * entire documents *	1-49
Y	US 5 599 974 A (D. J. ABRAHAM ET AL.) 4 February 1997 (1997-02-04) tables 1,2	1-49
y 1	WO 92 20335 A (CENTER FOR INNOVATIVE TECHNOLOGY) 26 November 1992 (1992-11-26) claims 1-12	· 1-49

International Application No PCT/US 00/22583

Y US 5 731 454 A (D. J. ABRAHAM ET AL.) 24 March 1998 (1998-03-24) 20 lumn 29, line 1 -column 29, line 29  Y US 5 432 191 A (D. J. ABRAHAM ET AL.) 11 July 1995 (1995-07-11) 20 lumn 21, line 23 -column 22, line 5; table 4	-49
Y US 5 731 454 A (D. J. ABRAHAM ET AL.) 24 March 1998 (1998-03-24) 20 lumn 29, line 1 -column 29, line 29  Y US 5 432 191 A (D. J. ABRAHAM ET AL.) 11 July 1995 (1995-07-11) 20 lumn 21, line 23 -column 22, line 5; 21 table 4  Y JP. VIGNERON: "Supramolecular Bioorganic Chemistry: Nucleic Acids Recognition and Synthetic Vectors for Gene Transfer" MOLECULES, vol. 4, 1999, pages 180-203, XP002156416	-49
24 March 1998 (1998-03-24)  column 29, line 1 -column 29, line 29  US 5 432 191 A (D. J. ABRAHAM ET AL.)  Ly July 1995 (1995-07-11)  column 21, line 23 -column 22, line 5;  table 4  JP. VIGNERON: "Supramolecular  Bioorganic Chemistry: Nucleic Acids  Recognition and Synthetic Vectors for Gene  Transfer"  MOLECULES,  vol. 4, 1999, pages 180-203, XP002156416	
12 July 1995 (1995-07-11)  column 21, line 23 -column 22, line 5; table 4   JP. VIGNERON: "Supramolecular Bioorganic Chemistry: Nucleic Acids Recognition and Synthetic Vectors for Gene Transfer" MOLECULES, vol. 4, 1999, pages 180-203, XP002156416	- <b>4</b> 9
Bioorganic Chemistry: Nucleic Acids Recognition and Synthetic Vectors for Gene Transfer" MOLECULES, vol. 4, 1999, pages 180-203, XP002156416	
	-49

Information on patent family members

International Application No
PCT/US 00/22583

Patent document cited in search repor	t	Publication date		Patent family member(s)	Publication date
EP 338916	A	25-10-1989	FR AT	2630329 A 77753 T	27-10-1989 15-07-1992
			DE	68901944 D	06-08-1992
			DE	68901944 T	10-12-1992
			ES	2043054 T	16-12-1993
			GR	3005220 T	24-05-1993
			JP	2042023 A	13-02-1990
			US	5110909 A	05-05-1992
WO 9742819	Α	20-11-1997	NON		
WO 9839358	Α	11-09-1998	US	5877220 A	02-03-1999
		, ·	AU 	6687998 A	22-09-1998
WO 9839359	Α	11-09-1998	US	6034135 A	07-03-2000
			AU	6448898 A	22-09-1998
			EP	0968227 A	05-01-2000
EP 452055	Α	16-10-1991	US	5114768 A	19-05-1992
			DE	69106562 D	23-02-1995
			DE	69106562 T	11-05-1995
US 5612207	Α	18-03-1997	AU	680890 B	14-08-1997
			AU	6415094 A	11-10-1994
			CA	2159005 A	29-09-1994
•			EP	0690671 A	10-01-1996
			JP WO	8511680 T 9421117 A	10-12-1996 29-09-1994
US 5927283		27-07-1999	 US	5677330 A	14-10-1997
			ÜS	5731454 A	24-03-1998
			US	5432191 A	11-07-1995
			US	5290803 A	01-03-1994
			US	5122539 A	16-06-1992
			US	5049695 A	17-09-1991
			US	5382680 A	17-01-1995
			US	5872282 A	16-02-1999
			US	5591892 A	07-01-1997 15-07-1007
			US US	5648375 A 5705521 A	15-07-1997 06-01-1998
			US	5661182 A	26-08-1997
			CA	2109575 A	26-11-1992
			EP	0585366 A	09-03-1994
			ĴΡ	3023423 B	21-03-2000
			JP	7508973 T	05-10-1995
			US	5250701 A	05-10-1993
			WO	9220335 A	26-11-1992
			US	5248785 A	28-09-1993
			CA	2051693 A	13-08-1991
•			DE	69115790 D	08-02-1996
		•	DE	69115790 -T	23-05-1996
			EP	0471811 A	26-02-1992
			JP JP	3023422 B 4506812 T	21-03-2000 26-11-1992
			WO	9112235 A	26-11-1992 22-08-1991
US 5872282		16-02-1999	US	5731454 A	24-03-1998

Information on patent family members

International Application No
PCT/US 00/22583

Patent document Patent family **Publication Publication** cited in search report member(s) date US US 5872282 5382680 A 17-01-1995 US 5591892 A 07-01-1997 US 5677330 A 14-10-1997 US 5648375 A 15-07-1997 US 5705521 A 06-01-1998 US 5927283 A 27-07-1999 US 5661182 A 26-08-1997 US 5250701 A 05-10-1993 US 5110909 05-05-1992 Α FR 2630329 A 27-10-1989 AT 77753 T 15-07-1992 68901944 D DE 06-08-1992 DE 68901944 T 10-12-1992 EP 0338916 A 25-10-1989 ES 2043054 T 16-12-1993 GR 3005220 T 24-05-1993 JP 2042023 A 13-02-1990 0420930 A US 4921997 Α 01-05-1990 EP 10-04-1991 JP 3505728 T 12-12-1991 WO 8912622 A 28-12-1989 US 5472981 A 05-12-1995 US 5093367 A 03-03-1992 US 5292935 A 08-03-1994 US 5079337 07-01-1992 2600894 A FR 08-01-1988 **AT** 67673 T 15-10-1991 CA 1328602 A 19-04-1994 DE 3773309 A 31-10-1991 EP 0259197 A 09-03-1988 ES 2026190 T 16-04-1992 WO 8800055 A 14-01-1988 GR 3003240 T 17-02-1993 JP 1500524 T 23-02-1989 JP 04300838 23-10-1992 NONE Α US 5599974 NONE Α 04-02-1997 WO 9220335 US 26-11-1992 5122539 A 16-06-1992 US 5248785 A 28-09-1993 CA 2109575 A 26-11-1992 EP 0585366 A 09-03-1994 JP 3023423 B 21-03-2000 JP 7508973 T 05-10-1995 US 5290803 A 01-03-1994 US 5250701 A 05-10-1993 US 5432191 A 11-07-1995 US 5731454 A 24-03-1998 US 5591892 A 07-01-1997 US 26-08-1997 5661182 A US 5677330 A 14-10-1997 US 5648375 A 15-07-1997 US 5705521 A 06-01-1998 US 27-07-1999 5927283 A US 5731454 24-03-1998 US Α 5432191 A 11-07-1995 US 5290803 A 01-03-1994

Information on patent family members

International Application No
PCT/US 00/22583

cited in search report	·	date		member(s)	date
US 5731454	Α		US	5382680 A	17-01-1995
			US	5122539 A	16-06-1992
			US	5049695 A	17-09-1991
			US	5872282 A	16-02-1999
			US	5591892 A	07-01-1997
			US	5677330 A	14-10-1997
			US	5648375 A	15-07-1997
			ÜS	5705521 A	06-01-1998
			US	5927283 A	27-07-1999
			US	5661182 A	26-08-1997
			US	5250701 A	05-10-1993
			CA	2109575 A	26-11-1992
			EP	0585366 A	09-03-1994
			JP ·	3023423 B	21-03-2000
			ĴР	7508973 T	05-10-1995
			WO	9220335 A	26-11-1992
			ÜS	5248785 A	28-09-1993
			CA	2051693 A	13-08-1991
			DE	69115790 D	08-02-1996
			DE	69115790 T	23-05-1996
			EP	0471811 A	26-02-1992
			ĴΡ	3023422 B	21-03-2000
			JP	4506812 T	26-11-1992
			Wo	9112235 A	22-08-1991
US 5432191	Α	11-07-1995	US	5290803 A	01-03-1994
			US	5382680 A	17-01-1995
			US	5122539 A	16-06-1992
			US	5049695 A	17-09-1991
			US	5872282 A	16-02-1999
			US	5731454 A	24-03-1998
			US	5591892 A	07-01-1997
			US	5661182 A	26-08-1997
			US	5677330 A	14-10-1997
			US	5648375 A	15-07-1997
			US	5705521 A	06-01-1998
			US	5927283 A	27-07-1999
	•		US	5250701 A	05-10-1993
			CA	2109575 A	26-11-1992
			EP	0585366 A	09-03-1994
			JP	3023423 B	21-03-2000
			JP	7508973 T	05-10-1995
			WO	9220335 A	26-11-1992
			US	5248785 A	28-09-1993
			CA	2051693 A	13-08-1991
			DE	69115790 D	08-02-1996
			DE	69115790 T	23-05-1996
			EP	0471811 A	26-02-1992
			JP	3023422 B	21-03-2000
			JP	4506812 T	26-11-1992
			WO	9112235 A	22-08-1991

## INTERNATIONAL PRELIMINARY International application No. PCT/US00/22583 EXAMINATION REPORT - SEPARATE SHEET

- 1. The Applicant is informed that this Opinion is based on the documents retrieved by the search. Due to the fact that this search was not carried out completely for all claims, since the cope of the claims are not clearly formulated this Examination Report cannot be complete.
- 2. From the state of the art as represented by the documents cited in the International Search Report numerous compounds which are similar in structure to compounds falling under the definition of Claim 11 are known to enhance the oxygen delivery in mammals.

Taking into account these facts the man skilled in the art would have to expect oxygen delivery enhancing capability without affecting their basic capabilities when modifying the basic moiety and/or the substituents of the groups of compounds disclosed in the state of the art. Thus representing only predictable effects the compounds claimed are considered to be obvious.

Consequently, Claims 1 to 49 are lacking inventive step under Article 33 (3) PCT.

3. The terms "lipophilic water-soluble molecule" and "ligand for a mammalian cellular receptor" are totally inappropriate in defining chemical compounds. The claims lack clarity (Article 6 PCT) since an attempt is made to define the compounds by reference to a result to be achieved rather than specifying their chemical structure by indicating the identity and number of the atoms involved.

Furthermore, the claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure.

With regard to the universe of different compounds falling under the scope of Claim 11 it is noted that a technical effect which justifies the selection of the claimed compounds must be one which can be assumed to be produced by substantially all the selected compounds. The numerous non-, mono- and polycyclic isocyclic and heterocyclic moieties being further substituted by numerous different groups as given in Claim 11 virtually encompass such an enormous number of compounds and that is by now way credible that all these variants represent solutions to the problem of providing improved  $\alpha$ -ammonium ketones as photoinitiators. There is no proven common general knowledge to show that the type of substituents that may be present in the claimed compounds would be irrelevant to the presence of the alleged properties.

For these reasons, and on the basis of what evidence there is in the case (only two actual working examples), the International Preliminary Examining Authority is not satisfied that substantially all compounds being claimed are likely to exhibit the alleged superior photoinitiating activity. Only those of the claimed compounds could possibly involve an inventive step which could be accepted as solutions of the technical problem of providing further compounds which